Karuna Therapeutics, Inc. KRTX reported a loss of $3.01 per share in fourth-quarter 2023, wider than the Zacks Consensus Estimate of a loss of $2.64. In the year-ago quarter, the company posted a loss ...

Karuna Therapeutics KRTX signed a definitive merger agreement with Bristol Myers Squibb BMY. Per the agreement terms, Bristol Myers will acquire all outstanding shares of Karuna for $330 per share in ...

Read full article: Walgreens to pay up to $350 million in opioid settlement, includes whistleblower compensation JSO drug evidence from a raid on a home in the Arlington area. FILE - In this June 15, ...

Neurological drugs developer Karuna Therapeutics is building up its pipeline with a pair of molecules initially developed for kidney disorders. It’s a small bet that could pay off in a big way by ...